18 results
10-K
2013 FY
ESPR
Esperion Therapeutics Inc.
13 Mar 14
Annual report
12:00am
was an eight-week Phase 2a clinical study in 58 patients, of whom 42 were dosed with ETC-1002, across six participating clinical recruitment sites in the United … participating clinical recruitment sites in the United States. This clinical study was designed to evaluate the LDL-C lowering efficacy, tolerability and safety
424B5
ESPR
Esperion Therapeutics Inc.
18 Jan 24
Prospectus supplement for primary offering
4:01pm
;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment or departure of key personnel
424B5
4dmy5lgg9my
22 Jan 24
Prospectus supplement for primary offering
6:04am
10-Q
1xorri c4
12 Aug 13
Quarterly report
12:00am
424B5
mop3ha2wfrjovorwm
2 Dec 21
Prospectus supplement for primary offering
5:22pm
424B5
lv2bnkssoe682
6 Dec 21
Prospectus supplement for primary offering
4:37pm
424B4
8cimhkgvt3p43 x4a
26 Jun 13
Prospectus supplement with pricing info
12:00am
S-1/A
nrm tvv99r
7 Jun 13
IPO registration (amended)
12:00am
424B5
1a2gi4cb1ct2j6jmb01
14 Oct 14
Prospectus supplement for primary offering
12:00am
424B5
iaudg89kocz4i5qwcn9
16 Oct 14
Prospectus supplement for primary offering
12:00am
DRS
ru14a9twz2bezane
12 Apr 13
Draft registration statement
12:00am
- Prev
- 1
- Next